. 2022 May 29;12(10):4629–4655. doi: 10.7150/thno.72465

Table 2.

Summary of different formulations for PDT-induced antitumor immunity by reprogramming TME. (↑= upregulation, ↓= downregulation)

Formulation	Therapeutic agents	Immune expression	Ref
DEX-HAase	Ce6, anti-PDL1	TAAs, IFN-γ, TNF-α, CD8⁺, mDC↑ HIF-1α, M2 macrophage↓	37
TOOKAD	WST11, anti-PD-1/anti-PD-L1	TAAs, CD4⁺, CD8⁺ ↑ Treg, PD-L1↓	43
FS@PMPt	Ce6, PFC	TAAs, mDC, CD4⁺, CD8⁺, TGF-β, IFN-γ↑ HIF-1α, Treg↓	22
PF₁₁DG	DiD	TAAs, mDC, NK, CD8⁺↑ MDSC, HIF-1α↓	52
FA-L@MD@CAT	MBDP, CAT	TAAs, mDC, CTL, M1 macrophage↑, M2, Treg, Hypoxia↓	54
MnO₂@chitosan-CyI	MnO₂, CyI	TAAs, CTL, IFN-γ, TNF-α↑ M2 macrophage, Hypoxia↓	56
CeO₂@MSNs@IR780/Met	CeO₂, IR780	TAAs, mDC, CD4⁺, CD8⁺↑ HIF-1α, PD-L1↓	59